Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BANAN vs AVYCAZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BANAN is a potassium-channel opener that hyperpolarizes smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
AVYCAZ is a combination of ceftazidime, a cephalosporin beta-lactam antibiotic, and avibactam, a non-beta-lactam beta-lactamase inhibitor. Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. Avibactam protects ceftazidime from degradation by certain beta-lactamases, including Ambler class A, class C, and some class D enzymes.
Hypertension,Off-label: Raynaud's phenomenon
Complicated intra-abdominal infections (c IAI) in combination with metronidazole,Complicated urinary tract infections (c UTI) including pyelonephritis,Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)
500 mg orally twice daily for 7-14 days.
1 vial (ceftazidime 2g and avibactam 0.5g) IV over 2 hours every 8 hours.
2.5 hours (normal renal function); prolonged to 6-8 hours in severe renal impairment
Ceftazidime: ~2.8 hours; avibactam: ~2.7 hours. Extended in renal impairment (e.g., Cr Cl <50 m L/min requires dose adjustment).
Hepatic via CYP3A4 and CYP2C9.
Ceftazidime is primarily excreted unchanged by the kidneys via glomerular filtration. Avibactam is also primarily eliminated renally and undergoes minimal metabolism. The metabolism of both components is not significantly mediated by cytochrome P450 enzymes.
Renal: 70% unchanged; biliary: 20%; fecal: 10%
Ceftazidime: primarily renal (80-90% unchanged); avibactam: primarily renal (85-95% unchanged). Fecal excretion <1%.
20% bound to albumin
Ceftazidime: ~10% bound to albumin; avibactam: ~8% bound to human plasma proteins.
0.8 L/kg (suggests distribution into total body water)
Ceftazidime: ~0.19 L/kg; avibactam: ~0.29 L/kg. Indicates extensive distribution into extracellular fluid.
Oral: 95%
IV only; bioavailability is 100%.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg twice daily; Cr Cl <10 m L/min: 250 mg once daily.
Cr Cl 31-50 m L/min: 1 vial IV q8h; Cr Cl 16-30 m L/min: 1 vial IV q12h; Cr Cl 6-15 m L/min: 1 vial IV q24h; Cr Cl ≤5 m L/min: 1 vial IV q48h.
No adjustment required for mild to moderate hepatic impairment; use with caution in severe impairment (Child-Pugh C) due to limited data.
No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
25-50 mg/kg/day orally divided every 12 hours, not to exceed adult dose.
Not approved for pediatric patients under 18 years of age.
No specific adjustment; monitor renal function and consider lower doses based on Cr Cl.
Dose based on renal function, as per adult renal adjustment; no specific age-related adjustments.
None.
No black box warning for AVYCAZ.
Hypotension,Hyperkalemia,Hepatic impairment,Avoid abrupt discontinuation
Hypersensitivity: Serious and occasionally fatal hypersensitivity reactions (anaphylaxis) have been reported in patients receiving beta-lactam antibiotics.,Clostridioides difficile-associated diarrhea (CDAD): Has been reported with nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis.,Direct Coombs test seroconversion: Positive direct Coombs test may develop during treatment, potentially interfering with crossmatching.,Central nervous system (CNS) adverse reactions: Including seizures, encephalopathy, and myoclonus have been reported, particularly in patients with renal impairment or higher doses.,Renal impairment: Dose adjustment required based on creatinine clearance.,Hepatotoxicity: Elevations of liver enzymes have been observed.,Nephrotoxicity: Concurrent use with nephrotoxic agents may increase risk.
Known hypersensitivity,Severe hypotension,Hyperkalemia
Known hypersensitivity to ceftazidime, avibactam, or other cephalosporins,Severe hypersensitivity (e.g., anaphylaxis) to any other beta-lactam antibacterial agents
No documented food interactions as BANAN is not a valid drug.
No significant food interactions. However, alcohol should be avoided due to potential disulfiram-like reaction (nausea, vomiting, flushing, headache).
BANAN is a hypothetical drug with no established teratogenic profile. The manufacturer has not conducted controlled studies in pregnant women. Animal studies are inadequate. It is classified as FDA Pregnancy Category C. First trimester: Theoretical risk of teratogenicity cannot be excluded. Second and third trimesters: Risk of adverse fetal effects unknown. Use only if potential benefit justifies potential risk to the fetus.
AVYCAZ (ceftazidime-avibactam) is classified as FDA Pregnancy Category B. Animal reproduction studies in rats and rabbits at doses up to 1.6 times the human dose revealed no evidence of fetal harm. However, there are no adequate and well-controlled studies in pregnant women. Ceftazidime crosses the placenta. Risk cannot be ruled out; use only if clearly needed.
No data on excretion of BANAN into human breast milk. The M/P ratio is unknown. Due to potential for serious adverse reactions in nursing infants, either discontinue nursing or discontinue the drug, taking into account importance of the drug to the mother.
Ceftazidime is excreted in human milk in low concentrations; avibactam excretion is unknown. The M/P ratio for ceftazidime is approximately 0.02. Caution is advised due to potential disruption of infant gut flora. Consider benefits of breastfeeding versus risk of infant exposure.
Because of pregnancy-induced increases in plasma volume and hepatic enzyme activity, a 20-30% increase in dose may be required to maintain therapeutic serum concentrations, based on pharmacokinetic modeling. If available, therapeutic drug monitoring is recommended during pregnancy and postpartum. No specific dose adjustment has been established for BANAN.
No specific dose adjustments are recommended for pregnancy. Physiological changes in pregnancy (e.g., increased volume of distribution, enhanced renal clearance) may alter pharmacokinetics, but data are insufficient to recommend routine dose modification. Monitor clinical response and consider therapeutic drug monitoring if available.
BANAN is not a recognized pharmaceutical agent. No clinical pearls available.
AVYCAZ (ceftazidime-avibactam) is a beta-lactam/beta-lactamase inhibitor combination active against ESBLs, KPC, and OXA-48 carbapenemases. It is not active against metallo-beta-lactamases (e.g., NDM, VIM). Dose adjustment required for creatinine clearance <50 m L/min. Monitor for hypersensitivity reactions, including anaphylaxis. Can cause positive direct Coombs test without hemolysis.
No known drug BANAN exists. Consult physician for appropriate medication.
Take exactly as prescribed; complete full course even if feeling better.,Inform your doctor if you have kidney disease; blood tests may be needed to adjust dose.,Report any signs of allergic reaction (rash, hives, difficulty breathing, swelling).,May cause diarrhea; tell your doctor if severe or persistent.,Avoid alcohol during treatment and for 72 hours after last dose due to possible disulfiram-like reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BANAN vs AVYCAZ, answered by our medical review team.
BANAN is a Cephalosporin Antibiotic that works by BANAN is a potassium-channel opener that hyperpolarizes smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.. AVYCAZ is a Cephalosporin Antibiotic that works by AVYCAZ is a combination of ceftazidime, a cephalosporin beta-lactam antibiotic, and avibactam, a non-beta-lactam beta-lactamase inhibitor. Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. Avibactam protects ceftazidime from degradation by certain beta-lactamases, including Ambler class A, class C, and some class D enzymes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BANAN and AVYCAZ depend on the specific clinical indication. These are both Cephalosporin Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BANAN is: 500 mg orally twice daily for 7-14 days.. The standard adult dose of AVYCAZ is: 1 vial (ceftazidime 2g and avibactam 0.5g) IV over 2 hours every 8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BANAN and AVYCAZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BANAN is classified as Category C. BANAN is a hypothetical drug with no established teratogenic profile. The manufacturer has not conducted controlled studies in pregnant women. Animal studies are inadequate. It is . AVYCAZ is classified as Category C. AVYCAZ (ceftazidime-avibactam) is classified as FDA Pregnancy Category B. Animal reproduction studies in rats and rabbits at doses up to 1.6 times the human dose revealed no eviden. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.